Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398140 | 0.80 | BRD4 (0.50) | ALDH1A1CRBNRAB9ATSHRKDM4E | |
| SCHEMBL9631384 | 0.76 | CRBN (0.67) | ALDH1A1CRBNADORA2ARAB9AHTT | |
| SCHEMBL20811718 | 0.73 | CRBN (0.76) | ALDH1A1CRBNTSHR | |
| SCHEMBL19359372 | 0.73 | CRBN (0.73) | ALDH1A1CRBNRAB9AHTTTSHR | |
| SCHEMBL5652611 | 0.70 | CRBN (0.67) | ALDH1A1CRBNTSHR | |
| SCHEMBL1398055 | 0.70 | CRBN (0.46) | ALDH1A1CRBNRAB9ATSHRKDM4E | |
| SCHEMBL24569651 | 0.70 | ADORA2A (0.46) | ALDH1A1ADORA2ARAB9AHTTPARP1 | |
| SCHEMBL4627301 | 0.70 | ADORA2A (0.46) | ALDH1A1ADORA2ARAB9AHTTPARP1 | |
| SCHEMBL5720522 | 0.70 | ADORA2A (0.46) | ALDH1A1ADORA2ARAB9AHTTPARP1 | |
| SCHEMBL6856036 | 0.70 | ADORA2A (0.46) | ALDH1A1ADORA2ARAB9AHTTPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2144885-B1 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI SA (FR) | 2016-06-29 | — | — | EP | disclosed |
| US-8735437-B2 | Imidazolidine carboxamide derivatives as lipase and phospholipase inhibitors | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| EP-2492322-A1 | Ink composition, image forming method, and printed material | Fujifilm Corporation (JP) | 2012-08-29 | — | — | EP | disclosed |
| US-20120213978-A1 | INK COMPOSITION, IMAGE FORMING METHOD, AND PRINTED MATERIAL | FUJIFILM CORPORATION (JP) | 2012-08-23 | — | — | US | disclosed |
| US-20100105719-A1 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI-AVENTIS (FR) | 2010-04-29 | — | — | US | disclosed |
| EP-2144885-A1 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | Sanofi-Aventis (FR) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008122352-A1 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-16 | — | — | WO | disclosed |
| US-7192967-B1 | Cyclic imide-substituted pyridylalkane, alkene, alkine carboxamides useful as cytostatic and immunosuppressive agents | ASTELLAS PHARMA GMBH (DE) | 2007-03-20 | — | — | US | disclosed |
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | disclosed |
| US-4001245-A | 2-[2-(Piperidino)ethyl]-10,10a-dihydro-1H,5H-imidazo[1,5-b]isoquinolin-1,3(2H)-dione | MORTON-NORWICH PRODUCTS, INC. (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037807-A1 | Pyridine compounds as inhibitors of dipeptidyl peptidase IV | DPP4, DPP3, PEPD | ALDH1A1 743/4885CRBN 2693/4885ADORA2A 3408/4885 |
| US-20100105719-A1 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | PNLIP, PLD1, PLD2 | ALDH1A1 577/4885CRBN 3738/4885ADORA2A 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.